新型头孢菌素BMY - 28142的纸片扩散法药敏初步判读标准
Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.
作者信息
Fuchs P C, Jones R N, Barry A L, Thornsberry C
出版信息
J Clin Microbiol. 1986 Mar;23(3):634-6. doi: 10.1128/jcm.23.3.634-636.1986.
Abstract
A total of 750 bacterial isolates, including 37 different species, were tested for susceptibility to BMY-28142 by standardized broth microdilution and disk diffusion tests. The zone diameter interpretive criteria tentatively suggested for the 30-micrograms BMY-28142 disk are as follows: susceptible = greater than or equal to 18 mm (MIC less than or equal to 8.0 micrograms/ml), resistant = less than or equal to 14 mm (MIC greater than or equal to 32 micrograms/ml), and indeterminate = 15 to 17 mm.
摘要
通过标准化肉汤微量稀释法和纸片扩散法，对总共750株细菌分离株（包括37个不同物种）进行了对BMY-28142的药敏试验。初步建议的针对含30微克BMY-28142纸片的抑菌圈直径解释标准如下：敏感 = 大于或等于18毫米（MIC小于或等于8.0微克/毫升），耐药 = 小于或等于14毫米（MIC大于或等于32微克/毫升），不确定 = 15至17毫米。
相似文献
1
Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.新型头孢菌素BMY - 28142的纸片扩散法药敏初步判读标准
J Clin Microbiol. 1986 Mar;23(3):634-6. doi: 10.1128/jcm.23.3.634-636.1986.
2
In vitro antibacterial spectrum of E1040 compared with those of cefpirome and ceftazidime and disk diffusion interpretive criteria for E1040.E1040的体外抗菌谱与头孢匹罗和头孢他啶的抗菌谱比较以及E1040的纸片扩散法解释标准。
Antimicrob Agents Chemother. 1990 May;34(5):914-7. doi: 10.1128/AAC.34.5.914.
3
Tentative disk diffusion susceptibility interpretive criteria for pefloxacin.培氟沙星纸片扩散法药敏试验初步解释标准。
J Clin Microbiol. 1986 Sep;24(3):448-50. doi: 10.1128/jcm.24.3.448-450.1986.
4
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.头孢噻肟：体外活性及纸片药敏试验的初步解释标准
Antimicrob Agents Chemother. 1980 Jul;18(1):88-93. doi: 10.1128/AAC.18.1.88.
5
Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.新型口服头孢菌素BMY-28100的纸片扩散药敏试验及肉汤微量稀释法质量控制指南
J Clin Microbiol. 1987 Nov;25(11):2211-3. doi: 10.1128/jcm.25.11.2211-2213.1987.
6
Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.头孢替坦，一种新型头孢霉素：与其他头孢菌素的体外抗菌活性比较、β-内酰胺酶稳定性及纸片扩散法检测的初步建议
Antimicrob Agents Chemother. 1982 Nov;22(5):859-77. doi: 10.1128/AAC.22.5.859.
7
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.BMY-28142与其他β-内酰胺类抗菌剂相比的体外活性。
Antimicrob Agents Chemother. 1985 Apr;27(4):515-9. doi: 10.1128/AAC.27.4.515.
8
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外活性评估
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
9
Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.头孢哌酮纸片扩散法药敏试验：暂定解释标准的确认、铜绿假单胞菌交叉耐药性及质量控制性能限度的测定
J Clin Microbiol. 1982 May;15(5):777-86. doi: 10.1128/jcm.15.5.777-786.1982.
10
In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin.新型氨噻唑基头孢菌素BMY 28142的体外活性
J Antimicrob Chemother. 1985 Oct;16(4):463-8. doi: 10.1093/jac/16.4.463.
引用本文的文献
1
Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.头孢吡肟与哌拉西林-庆大霉素治疗发热性中性粒细胞减少癌症患者的开放性随机研究。
Antimicrob Agents Chemother. 1997 Aug;41(8):1704-8. doi: 10.1128/AAC.41.8.1704.
2
Cefepime clinical pharmacokinetics.头孢吡肟的临床药代动力学。
Clin Pharmacokinet. 1993 Aug;25(2):88-102. doi: 10.2165/00003088-199325020-00002.
3
Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics.在常见大肠杆菌宿主背景中表达的β-内酰胺酶检测板的开发，用于评估新型β-内酰胺类抗生素。
Antimicrob Agents Chemother. 1995 Feb;39(2):308-13. doi: 10.1128/AAC.39.2.308.
4
Interpretive criteria for the agar diffusion susceptibility test with ofloxacin.氧氟沙星琼脂扩散药敏试验的解释标准。
Drugs. 1987;34 Suppl 1:14-9. doi: 10.2165/00003495-198700341-00004.
5
Preliminary interpretive criteria for the Haemophilus Test Medium method using 30 micrograms cefepime disks.使用30微克头孢吡肟纸片的嗜血杆菌检测培养基方法的初步解释标准。
Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):207-8. doi: 10.1007/BF01967086.
本文引用的文献
1
In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.新型广谱氨噻唑基α-甲氧基氨基头孢菌素HR810的体外评价
Antimicrob Agents Chemother. 1984 Jun;25(6):710-8. doi: 10.1128/AAC.25.6.710.
2
Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.将BMY-28142、头孢布宗和头孢匹胺的抗菌活性与其他头孢菌素的抗菌活性进行比较。
Antimicrob Agents Chemother. 1984 Oct;26(4):585-90. doi: 10.1128/AAC.26.4.585.
3
Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.临床微生物实验室中第四代头孢菌素HR810的纸片扩散法检测、质量控制指南及抗菌谱
J Clin Microbiol. 1984 Sep;20(3):409-12. doi: 10.1128/jcm.20.3.409-412.1984.
4
In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.头孢哌酮、头孢噻肟、拉氧头孢（LY127935）、阿洛西林、美洛西林及其他β-内酰胺类抗生素对淋病奈瑟菌和流感嗜血杆菌的体外抗菌活性，包括产β-内酰胺酶菌株。
Antimicrob Agents Chemother. 1980 Apr;17(4):757-61. doi: 10.1128/AAC.17.4.757.
5
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外活性评估
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
6
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.BMY-28142与其他β-内酰胺类抗菌剂相比的体外活性。
Antimicrob Agents Chemother. 1985 Apr;27(4):515-9. doi: 10.1128/AAC.27.4.515.
Zotero 插件